Cerapedics Closes $9M Venture Debt Financing from GE Capital

cerapedicsCerapedics, a Westminster, CO-based orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform, closed a $9m venture debt financing from GE Capital, Healthcare Financial Services.

The loan, which does not include equity or warrant coverage, will support general business operations for Cerapedics, including the advancement of Cerapedics’ United States regulatory process.

Led by and Glen Kashuba, chief executive officer, and Jeffrey G. Marx, Ph.D., president and chief operating officer, Cerapedics recently announced preliminary outcomes data from a FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures.
Preliminary analysis of the results indicated that treatment with i-FACTOR bone graft met the pre-specified primary end points.



Join the discussion